(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Kona SUV: The Courageous Minimized That is Catching Hearts Around the world - 2The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- 3Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
- 4Israeli military says it hit dozens of military facilities in Tehran
- 5Israeli Chief of Staff declares new border with Gaza Strip
- What's your #1 tone
- Toyota’s Next Big Sports Car Might Apparently Be a Turbocharged All-Paw Beast
- Countdown begins for long-awaited Artemis II moon mission
- In a scientific first, biologists recorded a wild wolf potentially using tools
- The most effective method to Recognize an Excellent Lab Precious stone
- The World's Dazzling Regular Miracles
- CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- Investigate These Retreats Well known With Seniors
- South America's Memorable Destinations: A Movement Guide
